AXIS CAPITAL HOLDINGS LIMITED (AXS): what the price requires
At today's price, AXIS CAPITAL HOLDINGS LIMITED (AXS) is priced for 11.1% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/AXS
Headline
| Field | Value |
|---|---|
| Ticker | AXS |
| Company | AXIS CAPITAL HOLDINGS LIMITED |
| Current price | $114.66/sh |
| Composition | Insurance 75% / Reinsurance 25% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | financials |
| Return on equity needed | 11.1% |
| Return on equity now | 16.9% |
| ROE gap | -5.8pp |
| Price-to-book | 1.45x |
Solve inputs: computed at a 8.9% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~1.5pp.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | +0.44σ |
| cohort percentile (of 80 peers) | 39 |
| sustained it ~10 years at this level | 73% |
| implied end-window share | 0% |
Valuation X-Ray
The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 0.72x | 3 | justifies |
| Earnings | 0.53x | 2 | justifies |
| Relative | 0.24x | 3 | justifies |
| Growth | 1.12x | 1 | expensive |
Families that justify the price: Asset, Earnings, Relative, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 3.1%); the inversion above states its own rate.
Per-Model Detail (n=9)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | — | — | no | — |
| Bank Fair Value (P/TBV) | — | $181.21 | 0.63x | yes | TBVPS $81.84 × 2.21x (ROE (TTM) 16.8% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 9.70% allowance/loans → ×0.80) |
| Relative Valuation | Relative | $173.14 | 0.66x | yes | P/E 11x (static sector reference · 2026-04), scenarios: 9.2x / 11.0x / 12.8x (bear / base = reference held flat / bull), EV/EBITDA 10x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $153.86 | 0.75x | yes | BV/sh $84.90, ROE (TTM) 16.8%, ke 9.3% |
| Two-Stage Excess Return | Asset | $204.44 | 0.56x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $102.30 | 1.12x | yes | Rev $6.7B, growth 11% (input: historical growth; tapered), Terminal P/S: 1.1x / 1.3x / 1.5x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $468.30 | 0.24x | yes | EPS $13.38, growth 35% (input: historical EPS growth), PEG=0.23 (Undervalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | $159.87 | 0.72x | yes | √(22.5 × EPS $13.38 × BVPS $84.90) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | $431.73 | 0.27x | yes | EPS $13.38 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | — | — | no | — |
| PEG Fair Value | Relative | $501.75 | 0.23x | yes | EPS $13.38 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $144.65 | 0.79x | yes | EPS $13.38 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Share count CAGR (buyback) | -3.3% |
Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).
Bullet Takeaways
At $101.05 Axis Capital trades well below most of its valuation methods, with the bank-style P/TBV mark near $181, the relative-multiple mark near $173, and the asset frames between $154 and $204. This is a value and asset-supported name: book, earnings power, and peer multiples all sit above the price.
The underwriting turnaround is the story. The Q1 2026 combined ratio of 89.8%, with insurance at 86.3%, marks a multi-year improvement from 99.9% in 2023, and a sub-90% combined ratio means the book is profitable before investment income. Annualized ROE ran 17%.
The valuation gap is wide and the priced-in assumption reads as within range, so the market is paying below tangible book value adjusted for returns. The risk in any specialty insurer is the catastrophe and reserve cycle, not the current multiple.
Bull Case
The structural advantage Axis has built is underwriting discipline in specialty lines, and the margin data proves it is real rather than rhetorical. From fiscal 2023 through Q1 2026 the company cut its combined ratio from 99.9% to 89.8% while growing gross premiums written from $8.4 billion toward a $9.9 billion run rate. A combined ratio below 90 means Axis earns an underwriting profit before a dollar of investment income, the mark of an insurer that prices risk well and walks away from business that does not clear its hurdle. That discipline is the moat, because in insurance the durable edge is saying no.
The Q1 2026 print shows the franchise compounding on that base. Net income rose 33% to $247.2 million, the combined ratio held at 89.8% with insurance at 86.3% and reinsurance at 92.7%, and annualized return on average common equity reached 17%. The insurance segment grew gross written premiums 20% year over year with underwriting income up 17% to $157 million, and the mix has tilted toward short-tail lines, now about 60% of premiums, which carry faster loss emergence and less reserve uncertainty than long-tail casualty. The FY2025 10-K detail on mortgage-market credit-risk-sharing transactions and other specialty exposures underscores a diversified specialty book rather than a concentrated bet.
An investor is paying well under return-justified book value for an insurer earning a 17% ROE with a sub-90 combined ratio. The characterization is value and asset-supported, not a growth bet, and that is exactly the setup where a re-rating toward book value plus continued underwriting profit can compound returns from a discounted entry.
Bear Case
The competitive reality Axis faces is that specialty and reinsurance pricing is cyclical and crowded: the same hard-market conditions that let Axis cut its combined ratio to 89.8% have drawn capital and competitors into specialty lines, and well-capitalized peers like Arch, Everest, and the Bermuda reinsurers are chasing the same short-tail business. When capacity floods in, rates soften, and the underwriting margin that the bull case rests on compresses across the industry, not just at Axis. The current sub-90 combined ratio reflects a favorable point in the pricing cycle, and competition is what ends favorable points.
The structural risk underneath that is the catastrophe and reserve cycle. An insurer's reported profitability can look excellent right up until a major catastrophe year or an adverse reserve development on prior accident years. Axis carries reinsurance exposure at a 92.7% combined ratio, the segment most sensitive to large natural-catastrophe losses, and a single heavy hurricane or wildfire season can swing a 90 combined ratio into the high 90s or worse. The shift toward short-tail lines reduces reserve-development uncertainty but raises catastrophe sensitivity, trading one risk for another. The trailing 17% ROE and 89.8% combined ratio are clean-year results; the question the price cannot answer is what the through-the-cycle average looks like once a bad cat year is included.
The valuation discount is real but it exists for a reason. Insurers trade below book when the market doubts the durability of the current margin or worries about reserve adequacy, and the gap between the $101 price (June 27, 2026) and the $154-to-$204 asset frames reflects that skepticism rather than a pure mispricing. The bet the bull makes is that Axis holds its underwriting edge as competition intensifies and absorbs the inevitable catastrophe years without eroding book value. If pricing softens, if a major cat year hits the reinsurance book, or if prior-year reserves prove light, the combined ratio drifts back up, the 17% ROE reverts, and the discount that looks like value turns out to be the market correctly pricing cyclical and tail risk.
Valuation
Axis is a financial, so the valuation runs on return on equity against tangible book value rather than a cash-flow lever. Against the $101.05 price, that model implies the stock trades at a meaningful discount to its return-justified value.
The model X-ray is consistent with a value and asset-supported name. Every applicable frame sits above the price: the P/TBV mark near $181, the relative P/E mark near $173 on an 11x sector median, simple excess return near $154, two-stage excess return near $204, and the Graham number near $160. The DCF, FCF, and EV/EBITDA methods do not apply to an insurer.
The spread is the information. The price is not a verdict on whether Axis is a good underwriter, the combined-ratio improvement says it has become one. It is a measure of how much cyclical and catastrophe risk the market is discounting: the gap between price and book is the premium the market demands for the chance that the current sub-90 combined ratio does not hold through a full cycle.
Catalysts
The near-term driver is the underwriting margin and premium growth. Q1 2026 delivered a combined ratio of 89.8%, with insurance at 86.3% and reinsurance at 92.7%, net income up 33% to $247.2 million, and a 17% annualized ROE. Insurance gross written premiums grew 20% with underwriting income up 17% to $157 million. Whether the sub-90 combined ratio holds as the company grows toward a $9.9 billion premium run rate is the swing factor.
The pricing cycle is the structural catalyst. The multi-year improvement from a 99.9% combined ratio in 2023 to 89.8% reflects a hard specialty market, and the watch item is whether rates stay firm or soften as capacity returns. The mix shift toward short-tail lines, now about 60% of premiums, changes the risk profile toward faster loss emergence and higher catastrophe sensitivity.
Catastrophe and reserve experience are the key risks. Watch combined-ratio trends by segment, gross-premium growth and rate adequacy, catastrophe losses through hurricane and wildfire seasons, prior-year reserve development, and capital actions including buybacks given the discount to book value.
Sources: StockTitan and GuruFocus (AXS Q1 2026 results, net income up 33% to $247.2M, combined ratio 89.8%, 17% annualized ROE), Simply Wall St and Investing.com (combined ratio detail by segment, insurance GWP up 20%, short-tail lines ~60% of premiums, combined ratio improvement from 99.9% in 2023, $8.4B to $9.9B premium growth).
Peer Cohorts (Per Segment, With Filing Citations)
Insurance (reported)
- WRB (W. R. BERKLEY CORP)
- (no filing in the citation store)
- ACGL (Arch Capital Group Ltd.)
- (no filing in the citation store)
- CNA (CNA FINANCIAL CORP)
- (no filing in the citation store)
- RLI (RLI Corp)
- (no filing in the citation store)
- MKL (MARKEL GROUP INC.)
- (no filing in the citation store)
- SIGI (SELECTIVE INSURANCE GROUP, INC)
- (no filing in the citation store)
- THG (HANOVER INSURANCE GROUP, INC.)
- (no filing in the citation store)
- EG (EVEREST GROUP, LTD.)
- (no filing in the citation store)
Reinsurance (reported)
- CB (Chubb Limited)
- (no filing in the citation store)
- TRV (Travelers Companies, Inc.)
- (no filing in the citation store)
- PGR (PROGRESSIVE CORP/OH/)
- (no filing in the citation store)
- ALL (ALLSTATE CORP)
- (no filing in the citation store)
- AIG (American International Group, Inc.)
- (no filing in the citation store)
- CINF (CINCINNATI FINANCIAL CORPORATION)
- (no filing in the citation store)
- HIG (The Hartford Insurance Group, Inc.)
- (no filing in the citation store)
- WRB (W. R. BERKLEY CORP)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.